Abd El-Aziz, G., Darwish, H., Morsy, A., Mousa, S. (2005). Serum level of Matrix metalloproteinase-9 in patients with systemic lupus erythematosus.. The Egyptian Journal of Hospital Medicine, 20(1), 1-7. doi: 10.21608/ejhm.2005.18088
Ghada A. Abd El-Aziz; Hanan M.A. Darwish; Amal A. Morsy; Sabila Gomma Mousa. "Serum level of Matrix metalloproteinase-9 in patients with systemic lupus erythematosus.". The Egyptian Journal of Hospital Medicine, 20, 1, 2005, 1-7. doi: 10.21608/ejhm.2005.18088
Abd El-Aziz, G., Darwish, H., Morsy, A., Mousa, S. (2005). 'Serum level of Matrix metalloproteinase-9 in patients with systemic lupus erythematosus.', The Egyptian Journal of Hospital Medicine, 20(1), pp. 1-7. doi: 10.21608/ejhm.2005.18088
Abd El-Aziz, G., Darwish, H., Morsy, A., Mousa, S. Serum level of Matrix metalloproteinase-9 in patients with systemic lupus erythematosus.. The Egyptian Journal of Hospital Medicine, 2005; 20(1): 1-7. doi: 10.21608/ejhm.2005.18088
Serum level of Matrix metalloproteinase-9 in patients with systemic lupus erythematosus.
1Departments of Dermatology Faculty of Medicine for girls Al-Azhar university
2Clinical pathology Faculty of Medicine for girls Al-Azhar university
3General Medicine Faculty of Medicine for girls Al-Azhar university
Abstract
Background: Matrix metalloproteinase-9 (MMP-9) was involved in inflammation and immune system dysfunctions. Beside immunologic abnormalities, systemic lupus erythematosus (SLE) also presents chronic inflammatory components. Therefore, a role of MMP-9 in SLE pathology might be supposed. Objective: To investigate the level of matrix metalloproteinase-9 in systemic lupus erythematosus patients and to determine its value in monitoring disease activity. Patients and methods: Twenty five SLE female patients were included in this study. Ten healthy females where selected as controls. The activity of SLE was evaluated according to SLAM scoring. Using quantitative ELISA Kit provided from R & D system INC. USA, to quantitate the total levels of MMP-9 . These levels were then compared and correlated with the ANA, anti-ds-DNA, lupus nephritis, Raynaud phenomenon, malar rash, photosensitivity, alopecia, and mucosal ulcers. Results: serum of MMP-9 were found to be significantly higher (P<0.01), in SLE patients compared to the control group. Serum MMP-9 show statistical significant correlation with anti- ds DNA, Lupus nephritis, Raynaud phenomenon, malar rash and photosensitivity and it did not- show any statistical significant correlation with ANA, alopecia and mucosal ulcers Conclusion : The data suggest that MMP-9 could be involved in the pathogenesis of SLE,
and serum MMP-9 can be used as marker progression and amelioration in SLE.